R
0.155
-0.02 (-8.82%)
| 前收盘价格 | 0.170 |
| 收盘价格 | 0.170 |
| 成交量 | 84,250 |
| 平均成交量 (3个月) | 283,316 |
| 市值 | 34,277,168 |
| 股市价格/股市净资产 (P/B) | 28.78 |
| 52周波幅 | |
| 利润日期 | 21 Feb 2024 - 26 Feb 2024 |
| 营业利益率 (TTM) | -408.60% |
| 稀释每股收益 (EPS TTM) | -0.030 |
| 季度收入增长率 (YOY) | -100.00% |
| 总债务/股东权益 (D/E MRQ) | 18.89% |
| 流动比率 (MRQ) | 1.58 |
| 营业现金流 (OCF TTM) | -6.14 M |
| 杠杆自由现金流 (LFCF TTM) | -3.63 M |
| 资产报酬率 (ROA TTM) | -93.69% |
| 股东权益报酬率 (ROE TTM) | -203.42% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (AU) | 混合的 | 混合的 |
| Diagnostics & Research (全球的) | 混合的 | 混合的 | |
| 股票 | RHYTHM BIO FPO | - | - |
AIStockmoo 评分
-0.9
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -3.0 |
| 平均 | -0.88 |
|
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Value |
| 内部持股比例 | 27.93% |
| 机构持股比例 | 2.73% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合